This 12-hour on-demand CME activity (originally took place on September 8-10, 2022 in Hilton Head Island, SC) examines various conditions often seen in everyday practice with the goal of learning new strategies for diagnosing and treating patients. This activity provides opportunities to get answers to your burning questions and learn ‘best practices’ tools and techniques to help you better treat your patients.
Every year, the American Diabetes Association (ADA) updates its evidence-based clinical practice guidelines, Standards of Medical Care in Diabetes. This article summarizes the changes most relevant to primary care practice.
In this CME activity, Dr. Javier Morales discusses the therapeutic interventions that will delay progression of diabetic kidney disease, as well as early screening utilizing UACR, eGRF and the KDIGO heat map. The association of medical renal disease and cardiovascular risk will be addressed as well.
On August 24, 2021, the U.S. Preventive Services Task Force (USPSTF) revised their recommendations for type 2 diabetes and pre-diabetes screening. The revision includes a recommendation that screening of all overweight and obese adults should begin at age 35 rather than age 40, per their previous recommendation in 2015.
Virginia is a well put-together woman in no apparent distress. Her vital signs this morning include a temperature of 98.6 F, heart rate of 55, and respiratory rate of 16. She has a BMI of 28. Virginia tells you that she has been feeling very fatigued lately. She has barely been able to get through her days without taking a nap, and she has definitely not been making it to the gym.
Roberta is a 56-year-old woman with a history of well-managed type 2 diabetes, hypertension, and peripheral vascular disease. She was first diagnosed with diabetes 5 years ago, but she has been working hard on managing her chronic disease since that time.
This activity will assist prescribers in basal insulin initiation and titration in these individuals. We will focus on treatments that allow patients to “self-titrate” their insulin doses while minimizing their risk of hypoglycemia. Barriers to insulin initiation as well as cultural concerns for insulin therapy will be addressed.
Hypoglycemia is the rate limiting step in managing diabetes intensively. Patients who experience treatment emergent hypoglycemia are at increased risk of cardiovascular death and all-cause mortality.
Primary care clinicians in all settings are frequently not meeting guideline-recommended performance measures for diabetes. Many clinicians cite an improved understanding of the mechanisms of action of anti-hyperglycemic agents in the context of T2DM pathophysiology as an urgent educational need.